| Literature DB >> 32204695 |
Leonard Abbeduto1, Elizabeth Berry-Kravis2, Audra Sterling3, Stephanie Sherman4, Jamie O Edgin5, Andrea McDuffie6, Anne Hoffmann2, Debra Hamilton4, Michael Nelson2, Jeannie Aschkenasy2, Angela John Thurman6.
Abstract
BACKGROUND: The evaluation of treatment efficacy for individuals with fragile X syndrome (FXS) or intellectual disability (ID) more generally has been hampered by the lack of adequate outcome measures. We evaluated expressive language sampling (ELS) as a procedure for generating outcome measures for treatment research in FXS. We addressed: (a) feasibility, (b) practice effects over two administrations, (c) test-retest reliability over the repeated administrations, and (d) construct validity. We addressed these issues for the full sample as well as for subgroups defined by age, IQ, and ASD status.Entities:
Keywords: Clinical trials; Expressive language; Fragile X syndrome; Outcome measures; Psychometrics; treatment
Mesh:
Year: 2020 PMID: 32204695 PMCID: PMC7092603 DOI: 10.1186/s11689-020-09313-6
Source DB: PubMed Journal: J Neurodev Disord ISSN: 1866-1947 Impact factor: 4.025
Participant characteristics
| Measure | SD | Range | |
|---|---|---|---|
| Chronological age | 14.8 | 4.6 | 6.5–23.8 |
| NVIQa,c | 46.4 | 6.2 | 42–68 |
| VIQa,d | 48.1 | 7.2 | 42–78 |
| Full scale IQa,c | 44.8 | 6.7 | 40–66 |
| ADOS severityb,e | 5.7 | 2.4 | 1–10 |
n = 106 unless indicated otherwise
aStanford-Binet, 5th edition standard scores
bSeverity score from Autism Diagnostic Observation Schedule, 2nd edition
cn = 103
dn = 105
en = 100
Feasibility of ELS procedures: compliance, number of C-units per sample, and completeness
| ELS procedure | Test | Retest |
|---|---|---|
| Noncompliant | 15 (14.2%) | 6 (5.7%) |
| < 50 C-units (total) | 5 (4.7%) | 4 (3.9%) |
| < 50 C-units (analysis set) | 11 (10.4%) | 12 (11.7%) |
| Incomplete conversationsa | 16 (15%) | 11 (11%) |
| Noncompliant | 15 (14.2%) | 9 (8.5%) |
| < 25 C-units (total) | 13 (12.3%) | 10 (9.7%) |
| < 25 C-units (analysis set) | 27 (25.5%) | 22 (21.4%) |
| Incomplete narrativesb | 27 (25%)c | 22 (21%)d |
Cell values are number (and percentages) of participants, with n = 106 for first and 103 for retest administrations, respectively, unless noted otherwise
aDefined in terms of duration
bDefined in terms of coverage of pages
cn = 105
dn = 102
Characteristics of compliant and noncompliant participants
Shaded cells reflect p values that are significant according to the FDR procedure. n for compliant ranges from 81 to 87 per measure for conversation and 83 to 89 for narration. n for noncompliant ranges from 15 to 16 per measure for conversation and 13 to 14 for narration
aStanford-Binet, 5th edition transformed scores (Sansone et al. [23])
bTotal severity score from Autism Diagnostic Observation Schedule, 2nd edition
Practice effects on repeated administrations over a 4-week interval
| Conversation ( | Narration ( | |||||||
|---|---|---|---|---|---|---|---|---|
| Measure | Visit 1 | Retest | Visit 1 | Retest | ||||
| SD | SD | SD | SD | |||||
| 77.99 | 31.78 | 82.43 | 34.01 | 67.13 | 31.66 | 69.56 | 31.97 | |
| 3.64 | 1.39 | 3.81 | 1.46 | 4.80 | 2.13 | 4.96 | 2.20 | |
| 14.56 | 5.40 | 14.84 | 4.96 | 12.24 | 5.59 | 12.15 | 5.11 | |
| 0.15 | 0.13 | 0.16 | 0.15 | 0.16 | 0.17 | 0.16 | 0.16 | |
| 0.20 | 0.13 | 0.21 | 0.13 | 0.17 | 0.12 | 0.19 | 0.14 | |
None of the t tests comparing the first and retest administrations was significant at p < .050 (even uncorrected for multiple tests)
Test-retest reliability over a 4-week interval: bivariate correlations and intraclass correlations
Note that uncorrected p values for individual tests are marked with asterisks as follows: ***signifies p ≤ .0005; **signifies p ≤ .005; **signifies p ≤ .050. Shaded cells contain values that were significant at p ≤ .050 after correcting for multiple tests through the FDR procedure
Construct validity: conversation
Note that all values are bivariate zero-order correlations except for that between dysfluency and the SB5 VWM score, which is a partial correlation controlling for syntax (MLU). n = 83–87 across correlations. Uncorrected p values for individual tests are marked with asterisks as follows: ***signifies p ≤ .0005; **signifies p ≤ .005; **signifies p ≤ .050. Shaded cells contain values that were significant at p ≤ .050 after correcting for multiple tests through the FDR procedure. The boldfaced values represent convergent validity relationships; all other values represent discriminant validity relationships
ap > .050 in Spearman (nonparametric) analysis
bp ≤ .050 in Spearman (nonparametric) analysis
Construct validity: narration
Note that all values are bivariate zero-order correlations except for that between dysfluency and the SB5 VWM score, which is a partial correlation controlling for syntax (MLU). n = 85–89 across correlations. Uncorrected p values for individual tests are marked with asterisks as follows: ***signifies p ≤ .0005; **signifies p ≤ .005; **signifies p ≤ .050. Shaded cells contain values that were significant at p ≤ .050 after correcting for multiple tests through the FDR procedure. The boldfaced values represent convergent validity relationships; all other values represent discriminant validity relationships
Intercorrelations among ELS measures: conversation
Note that all values are bivariate zero-order correlations. n = 87 for all correlations. Uncorrected p values for individual tests are marked with asterisks as follows: ***signifies p ≤ .0005; **signifies p ≤ .005; **signifies p ≤ .050. Shaded cells contain values that were significant at p ≤ .050 after correcting for multiple tests through the FDR procedure
Intercorrelations among ELS measures: narration
Note that all values are bivariate zero-order correlations. n = 89 for all correlations. Uncorrected p values for individual tests are marked with asterisks as follows: ***signifies p ≤ .0005; ** signifies p ≤ .005; ** signifies p ≤ .050. Shaded cells contain values that were significant at p ≤ .050 after correcting for multiple tests through the FDR procedure